CAMV-01
/ Cambium Oncology
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 02, 2026
CAMV-01 targets VIP signaling, a novel immune checkpoint pathway, for the treatment of acute myeloid leukemia
(SITC 2026)
- No abstract available
Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology
1 to 1
Of
1
Go to page
1